Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

Clinical trial NCT04572854 · COMPLETED

Trial details

NCT number: NCT04572854
Sponsor: Apellis Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

C3G IC-MPGN Renal Transplant Complement 3 Glomerulopathy Complement 3 Glomerulopathy (C3G)Dense Deposit Disease (DDD)Membranoproliferative Glomerulonephritis Membranoproliferative Glomerulonephritis (MPGN)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)C3 Glomerulopathy C3 Glomerulonephritis Complement 3 Glomerulonephritis

Start date: 2021-09-07
Primary completion: 2023-02-27
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.